Interleukin-17A and Keratinocytes in Psoriasis

Int J Mol Sci. 2020 Feb 13;21(4):1275. doi: 10.3390/ijms21041275.

Abstract

The excellent clinical efficacy of anti-interleukin 17A (IL-17A) biologics on psoriasis indicates a crucial pathogenic role of IL-17A in this autoinflammatory skin disease. IL-17A accelerates the proliferation of epidermal keratinocytes. Keratinocytes produce a myriad of antimicrobial peptides and chemokines, such as CXCL1, CXCL2, CXCL8, and CCL20. Antimicrobial peptides enhance skin inflammation. IL-17A is capable of upregulating the production of these chemokines and antimicrobial peptides in keratinocytes. CXCL1, CXCL2, and CXCL8 recruit neutrophils and CCL20 chemoattracts IL-17A-producing CCR6+ immune cells, which further contributes to forming an IL-17A-rich milieu. This feed-forward pathogenic process results in characteristic histopathological features, such as epidermal hyperproliferation, intraepidermal neutrophilic microabscess, and dermal CCR6+ cell infiltration. In this review, we focus on IL-17A and keratinocyte interaction regarding psoriasis pathogenesis.

Keywords: CCL20; CXCL1; CXCL8; ILC3; Koebner phenomenon; Th17; antimicrobial peptides; interleukin-17A; keratinocytes; psoriasis.

Publication types

  • Review

MeSH terms

  • Cell Proliferation / genetics
  • Chemokine CCL20 / genetics
  • Chemokine CXCL1 / genetics
  • Chemokine CXCL2 / genetics
  • Epidermis / metabolism*
  • Epidermis / pathology
  • Humans
  • Interleukin-17 / genetics*
  • Interleukin-8 / genetics
  • Keratinocytes / metabolism*
  • Keratinocytes / pathology
  • Neutrophils / metabolism
  • Neutrophils / pathology
  • Psoriasis / genetics*
  • Psoriasis / pathology

Substances

  • CCL20 protein, human
  • CXCL1 protein, human
  • CXCL2 protein, human
  • CXCL8 protein, human
  • Chemokine CCL20
  • Chemokine CXCL1
  • Chemokine CXCL2
  • IL17A protein, human
  • Interleukin-17
  • Interleukin-8